Cancer-killing virus could improve precision medicine
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
A new imaging method called FLASH can provide a visualisation of several tissue types in a 3D format, its developers say.
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
In pre-clinical studies, researchers have shown that a new therapy called POMHEX can destroy brain cancer cells that were missing one of two genes encoding the enolase enzyme.
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
Researchers say their new process enables the synthesis of phenazinones, some of which have high selective toxicity for cancer cells and could be promising anticancer drugs in future.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
A team has extracted single tumour cells from existing cell lines to create 3D cell cultures that could allow for personalised cancer therapies.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Scientists have shown that age may cause genetically identical melanoma skin cancer cells to respond differently to treatment, making age a primary factor in treatment response.
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.